Cargando…
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced gly...
Autores principales: | Triplitt, Curtis, Cornell, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610726/ https://www.ncbi.nlm.nih.gov/pubmed/26523120 http://dx.doi.org/10.4137/CMED.S31526 |
Ejemplares similares
-
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018) -
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014) -
Emerging treatments in type 2 diabetes: focus on canagliflozin
por: Rosiak, Marek, et al.
Publicado: (2014) -
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017) -
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)